Floatz logo

Armodafinil

Nervous System Tumors

Wake Forest University Health SciencesSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Nervous System Tumors cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Hoffmann-La Roche
Phase 3BB
Carboplatin
Blueprint Medicines Corporation
Phase 3BB
Pralsetinib, trans-
Hoffmann-La Roche
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Hoffmann-La Roche
Phase 3B
Microbubble
NaviFUS Corporation
Phase 3B

View all 13 →

Same molecule, other indications

Armodafinil is also rated in:

Obstructive Sleep ApneaDormant
BB
Indicative ·
69 / 100
View asset →
sleep disorderDormant
BB
Indicative ·
69 / 100
View asset →
dysthymic disorderDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →